3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with Liver Neoplasms in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Baldini, MT; Buraggi, GL; Cascinelli, N; Castellani, MR; Gasparini, M; Maffioli, L; Mascheroni, L; Mongioj, V; Seregni, E | 1 |
1 trial(s) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Liver Neoplasms
Article | Year |
---|---|
Scintigraphic detection of melanoma metastases with a radiolabeled benzamide ([iodine-123]-(S)-IBZM).
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Contrast Media; Dopamine Antagonists; Evaluation Studies as Topic; Female; Humans; Iodine Radioisotopes; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Pyrrolidines; Radiation Dosage; Skin Neoplasms; Tomography, Emission-Computed, Single-Photon | 1994 |